Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA partners with Drugs.com

This article was originally published in The Tan Sheet

Executive Summary

Drugs.com will provide visitors FDA consumer updates through a partnership announced May 26. The arrangement will enhance FDA's "effort to ensure the public has easy access to reliable, useful information that can help people protect and improve their health," the agency says. FDA also partners with WebMD and Everyday Health to bolster consumer outreach (1"The Tan Sheet" Nov. 30, 2009, In Brief)

You may also be interested in...



FDA, Everyday Health join forces

The agency's collaboration with consumer health information network Everyday Health will allow FDA's food and medical product safety alerts and postings about wellness and prevention to reach Everyday Health's 30 million unique monthly visitors. The Web site's owner, Waterfront Media, and FDA launched the co-branded portal 1www.EverydayHealth.com/FDA, and will jointly publish a weekly newsletter on drug safety, children's health products and cosmetics, according to a Nov. 17 release. FDA also works with WebMD to communicate with consumers (2"The Tan Sheet" Nov. 2, 2009, In Brief)

J&J To Power Ahead With 10 Launches In Four Years

 Johnson & Johnson has achieved exceptional growth in recent years, and a raft of new products is set to sustain it further. 

Bayer's Efforts To Pioneer Tumor-Agnostic Market In Europe Held Back

Bayer’s drive to lead a new market opportunity in Europe for histology-independent cancer agents like Vitrakvi has been set back by interim decisions from the UK’s NICE and Germany’s IQWiG, but there is a now a clear pathway to follow.

 

Topics

UsernamePublicRestriction

Register

PS104151

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel